Review
Oct 2026
Do progression-free survival benefits justify increased toxicity and treatment burden? A meta-regression analysis of phase III immune checkpoint inhibitor trials from a value-based oncology perspective.
PFS showed a limited and treatment-type-dependent association with OS, and PFS gains frequently accompanied increased toxicity.
Zhen-Yang Long, Tian-Tian You, Yu-Qi Zhao
· Clinical and Translational O... · 0 citations